LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

20.18 -0.3

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.06

Максимум

20.7

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+93.7% upside

Дивиденти
By Dow Jones
Следващи печалби	2.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	651M 1.8B
Предишно отваряне	20.48
Предишно затваряне	20.18

Настроения в новините

By Acuity

32%

68%

93 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.02.2026 г., 23:44 ч. UTC

Горещи акции

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17.02.2026 г., 23:20 ч. UTC

Печалби

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17.02.2026 г., 22:57 ч. UTC

Печалби

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17.02.2026 г., 21:59 ч. UTC

Печалби

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17.02.2026 г., 23:54 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17.02.2026 г., 23:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

17.02.2026 г., 23:54 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.02.2026 г., 23:45 ч. UTC

Пазарно говорене

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17.02.2026 г., 23:19 ч. UTC

Печалби

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17.02.2026 г., 23:15 ч. UTC

Печалби

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17.02.2026 г., 22:58 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17.02.2026 г., 22:58 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17.02.2026 г., 22:57 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17.02.2026 г., 22:50 ч. UTC

Придобивния, сливания и поглъщания

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17.02.2026 г., 22:44 ч. UTC

Печалби

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17.02.2026 г., 22:42 ч. UTC

Печалби

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17.02.2026 г., 22:36 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17.02.2026 г., 22:36 ч. UTC

Печалби

Santos Final Dividend 10.3 U.S. Cents/Security

17.02.2026 г., 22:36 ч. UTC

Печалби

Santos FY Underlying Profit US$898 Million, Down 25%

17.02.2026 г., 22:35 ч. UTC

Печалби

Santos FY Revenue US$4.94 Billion, Down 8%

17.02.2026 г., 22:35 ч. UTC

Печалби

Correct: Santos FY Net Profit US$818 Million, Down 33%

17.02.2026 г., 22:35 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17.02.2026 г., 22:34 ч. UTC

Печалби

Santos FY Net Profit US$818 Billion, Down 33%

17.02.2026 г., 22:02 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17.02.2026 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

17.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

17.02.2026 г., 21:49 ч. UTC

Придобивния, сливания и поглъщания

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17.02.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17.02.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

93.7% нагоре

12-месечна прогноза

Среден 39.67 USD 93.7%

Висок 56 USD

Нисък 28 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

93 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.